Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NECTAR
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 1 Aug 2017 to 1 Aug 2019.
- 23 Jul 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2019.